Truncated ATP7B AAV Vector for Wilson Disease Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Wilson disease, such as chelating agents and liver transplantation, are not effective for all patients and require immune suppression, while existing gene therapy approaches lack efficiency and manufacturing ease.
Innovation Solution
A recombinant adeno-associated virus (AAV) vector is used to deliver a truncated yet functional ATP7B protein, lacking metal-binding domains 1-3 but retaining the serine-rich loop between MBD3 and MBD4, to treat Wilson disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chelating agents are used for treatment, then copper removal is achieved, but treatment effectiveness is limited and not all patients respond
Solution Approach 1:
The invention extracts and delivers only the essential functional domains (MBDs 4-6 and serine-rich loop) of ATP7B via AAV vector, omitting non-essential portions (MBDs 1-3). This truncated version achieves reliable copper excretion in hepatocytes without requiring patient-specific customization, resolving the contradiction between treatment reliability and patient response variability.
2Reliability
If liver transplantation is performed, then copper removal capability is restored, but immune suppression is required
Solution Approach 1:
Instead of transplanting an entire organ, the invention extracts and delivers only the critical copper-transporting functional domains of ATP7B protein via AAV vector. This approach restores copper excretion function without the complexity of lifelong immune suppression, directly resolving the contradiction between functional reliability and treatment complexity.
3Reliability
If wild-type ATP7B is used in gene therapy, then full functionality is achieved, but manufacturing efficiency is reduced
Solution Approach 1:
The invention removes metal-binding domains 1-3 from the ATP7B protein sequence while retaining domains 4-6 and the serine-rich loop. This truncation reduces protein size and simplifies manufacturing processes, improving productivity while maintaining sufficient copper transport functionality through the retained domains.
Solution Approach 2:
The invention concentrates the therapeutic activity in the essential local regions (MBDs 4-6 and serine-rich loop) rather than requiring the entire protein structure. This localized functional approach maintains reliability while enabling more efficient manufacturing of the truncated protein variant.
4Ease of manufacture
If truncated ATP7B is used, then manufacturing ease is improved, but treatment efficacy may be reduced
Solution Approach 1:
The invention strategically retains the locally essential MBDs 4-6 and serine-rich loop regions that contain the critical copper-binding and transport functions. This localized preservation ensures treatment efficacy is maintained while the removal of non-essential MBDs 1-3 provides manufacturing advantages, resolving the contradiction between ease of manufacture and treatment efficacy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This application relates to adeno-associated viral vectors encoding a truncated yet functional ATP7B for use in gene therapy for treating Wilson disease (WD). The truncated ATP7B described herein has several advantages over the wild-type ATP7B such as higher efficacy and improved manufacturing yield.